12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Other News

Summit musculoskeletal, infectious news

Summit said it will focus on the clinical development of programs for Duchenne muscular dystrophy (DMD) and Clostridium difficile infections. The company said the change in strategy will "curtail internal discovery-stage research," which is conducted by about half of the company, and said...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >